Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Autor: Dougados, M., Wei, J.C.C., Landewe, R., Sieper, J., Baraliakos, X., Bosch, F. van den, Maksymowych, W.P., Ermann, J., Walsh, J.A., Tomita, T., Deodhar, A., Heijde, D. van der, Li, X.Q., Zhao, F.Y., Bertram, C.C., Gallo, G., Carlier, H., Gensler, L.S., COAST-V Study Grp, COAST-W Study Grp

Publikováno v: Annals of the rheumatic diseases, 79(2), 176-185. BMJ Publishing Group
Annals of the Rheumatic Diseases, vol 79, iss 2
ANNALS OF THE RHEUMATIC DISEASES
Annals of the Rheumatic Diseases, 79(2), 176-185. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases

ObjectivesTo investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b33b5b111a36e83838fcfbbce49c6fe
https://pure.amc.nl/en/publications/efficacy-and-safety-of-ixekizumab-through-52-weeks-in-two-phase-3-randomised-controlled-clinical-trials-in-patients-with-active-radiographic-axial-spondyloarthritis-coastv-and-coastw(b7016626-7f8a-4c62-bd23-58a44a9373f3).html